Development of macrocyclic peptide inhibitors of Mycobacterium tuberculosis MurF via mRNA display with genetic reprogramming.
The development of new antibacterials for Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains critical due to the continued global burden of disease and the emergence of multi-drug resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. The MurF enzyme, which catalyses the AT...